<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006004</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068012</org_study_id>
    <secondary_id>E-1599</secondary_id>
    <nct_id>NCT00006004</nct_id>
  </id_info>
  <brief_title>Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which combination chemotherapy regimen is more effective for treating non-small&#xD;
      cell lung cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of two combination&#xD;
      chemotherapy regimens in treating patients who have non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare overall survival, response rate, and time to progression of patients with&#xD;
           non-small cell lung cancer treated with paclitaxel and carboplatin versus gemcitabine&#xD;
           and cisplatin.&#xD;
&#xD;
        -  Compare the toxicities of each of these 2 regimens in this patient population.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to weight&#xD;
      loss in the past 6 months (less than 5% vs at least 5%) and disease stage (stage IIIB with&#xD;
      pleural or pericardial effusion or pleural implants vs stage IV/recurrent). Patients are&#xD;
      randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30&#xD;
           minutes on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by&#xD;
           cisplatin IV over 1 hour on day 1 only.&#xD;
&#xD;
      Treatment continues in both arms every 21 days for up to 6 courses in the absence of&#xD;
      unacceptable toxicity or disease progression.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 40-90 patients (20-45 per arm) will be accrued for this&#xD;
      study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung carcinoma of any of the&#xD;
             following subtypes:&#xD;
&#xD;
               -  Squamous cell&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Large cell anaplastic&#xD;
&#xD;
               -  Bronchioalveolar&#xD;
&#xD;
               -  Non-small cell carcinoma not otherwise specified&#xD;
&#xD;
          -  No small cell anaplastic elements allowed&#xD;
&#xD;
          -  Must have:&#xD;
&#xD;
               -  Recurrent disease after prior radiotherapy or surgery OR&#xD;
&#xD;
               -  Stage IV disease with distant metastases OR&#xD;
&#xD;
               -  Stage IIIB disease presenting with pleural or pericardial effusion on CT or chest&#xD;
                  x-ray or pleural implants documented pathologically or on CT or chest x-ray&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease&#xD;
&#xD;
          -  Brain metastases allowed provided clinically stable after treatment with surgery&#xD;
             and/or radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled high blood pressure, unstable angina, or congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No serious ventricular arrhythmias requiring medication&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other active malignancies requiring ongoing treatment&#xD;
&#xD;
          -  No uncontrolled serious active infections&#xD;
&#xD;
          -  No suspected hypersensitivity to agents that utilize Cremophor&#xD;
&#xD;
          -  No evidence of neuropathy grade 2 or greater by history or physical examination&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for non-small cell lung cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radiotherapy to only site of measurable or evaluable disease unless&#xD;
             subsequent progression documented by physical exam, radiograph, or pathology&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy except for whole brain radiation for developing brain&#xD;
             metastases&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey J. Langer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Lutheran Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50316-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegent Health-Midlands Community Hospital</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68128-4157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - University of New Mexico HSC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Vincent Hospital Cancer Center, Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54307-3453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936-7344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH; Eastern Cooperative Oncology Group. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol. 2007 Feb 1;25(4):418-23. doi: 10.1200/JCO.2005.04.9452.</citation>
    <PMID>17264337</PMID>
  </results_reference>
  <results_reference>
    <citation>Tester WJ, Stephenson P, Langer CJ, et al.: ECOG 1599: randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC). [Abstract] J Clin Oncol 22 (Suppl 14): A-7055, 630s, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Langer CJ, Stephenson P, Schiller J, et al.: ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. [Abstract] Lung Cancer 41 (Suppl 2): A-O52, S18, 2003.</citation>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>adenosquamous cell lung cancer</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

